Back to results
US 12,098,426 B2Granted
Gene expression markers and treatment of multiple sclerosis
AssigneeGenentech, Inc.
InventorsMichael Townsend, Alvernia Francesca Setiadi, Tracy Staton
Life of this patent
Estimating the term…
Abstract
The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
Claims8
A method of treating a mammalian subject suffering from multiple sclerosis (MS), comprising:
- a) measuring an expression level of leucine-rich alpha-2-glycoprotein 1 (LRG1) in a cerebrospinal fluid (CSF) sample of the subject;
- b) comparing the expression level of LRG1 measured in a) to a reference expression level of LRG1 in a CSF sample of an MS-negative control;
- and
- c) administering an effective amount of an interleukin 17 (IL-17) antagonist to the subject whose expression level of LRG1 measured in a) is above the reference expression level;
- wherein the IL-17 antagonist is an anti-IL-17 antibody or an anti-IL-17 receptor antibody.
2 more elements
Dependencies are inferred from the claim text.